Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.
Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.